Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Gets 340B Appeals Court Victory But More Decisions Are Pending; Will Congress Step In?

Executive Summary

Third Circuit is first of three federal appeals courts to issue a decision in multiple lawsuits over drug companies’ 340B contract pharmacy restrictions, which have led to conflicting lower court rulings on whether such restrictions are unlawful.

You may also be interested in...

340B Court Decision Threatens To Expand Patient Eligibility; Can Pharmacy Restrictions Counter Program Growth?

Court ruling in litigation brought against the US government by Genesis Healthcare may elicit competing reactions among stakeholders but is expected to stir up the 340B market.

340B Drug Discount Fight Moves To States As PhRMA Opposes Louisiana Law

PhRMA points to federal court rulings against HHS’s view that companies cannot limit discounts to contract pharmacies. However, there is a split among district courts and while one appellate court has sided with industry two have yet to issue opinions.

340B Discounts Linked To Lower Hospital Costs For COPD When Savings Pass Directly To Patients

Research is published as the US Congress gears up to explore reforms of the 340B program. The findings align with pharma’s push to ‘share the savings’ but are not currently typical in the program, the Pharmaceutical Research and Manufacturers of America maintains.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts